Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Breast Neoplasms 3Pancreatic Neoplasms 2Melanoma 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Neoplastic Cells, Circulating 1Myelodysplastic Syndromes 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Pancreatic Cancer 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Melanoma × Digoxin × Clear all
NCT02138292 2018-05-15

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

University of Texas Southwestern Medical Center

Phase 1 Completed
27 enrolled
Dermatologic

Melanoma

NCT02915666 2018-05-15

A Clinical Trial of Patients With Melanoma

University of Texas Southwestern Medical Center

Phase 1 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡